Evidence map›Paper›PMID 35751930›Full record

ReviewJournal of infection and public health2022

MicroRNAs in the development of potential therapeutic targets against COVID-19: A narrative review.

Jivan Qasim Ahmed, Sazan Qadir Maulud, Manish Dhawan, Priyanka, Om Prakash Choudhary, Paywast Jamal Jalal, Rezhna Kheder Ali, Gahin Abdulraheem Tayib, Dlshad Abdullah Hasan

Open access · goldAbstract readReview
In one paragraph

Review in Journal of infection and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Annals of medicine and surgery (2012) · 2023
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Frontiers in cellular and infection microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Jivan Qasim AhmedDepartment of Pathology and Microbiology, University of Duhok, Kurdistan Region, Iraq.
Sazan Qadir MauludDepartment of Biology, College of Education, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Manish DhawanDepartment of Microbiology, Punjab Agricultural University, Ludhiana, 141004 Punjab, India; Trafford College, Altrincham, Manchester, WA14 5PQ, UK.
PriyankaDepartment of Veterinary Microbiology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences University (GADVASU), Rampura Phul, Bathinda 151103, Punjab, India. Electronic address: priyanka7malik@gmail.com.
Om Prakash ChoudharyDepartment of Veterinary Anatomy and Histology, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University (I), Selesih, Aizawl, 796015, Mizoram, India. Electronic address: dr.om.choudhary@gmail.com.
Paywast Jamal JalalDepartment of Biology, College of Science, University of Sulaimani, Kurdistan Region, Iraq.
Rezhna Kheder AliDepartment of Biology, College of Education, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Gahin Abdulraheem TayibDepartment of Pathology and Microbiology, University of Duhok, Kurdistan Region, Iraq.
Dlshad Abdullah HasanPublic Health Laboratory Management-Erbil, Kurdistan Region, Iraq.
Salahaddin University-Erbil · IQUniversity of Duhok · IQCentral Agricultural University · INGuru Angad Dev Veterinary and Animal Sciences University · INPunjab Agricultural University · INUniversity of Sulaimani · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs the therapeutic regimens against the COVID-19 remain scarce, the microRNAs (miRNAs) can be exploited to generate efficient therapeutic targets. The miRNAs have been found to play pivotal roles in the several regulatory functions influencing the prognosis of viral infection. The miRNAs have a prospective role in the up and down regulation of the ACE2 receptors. This review examines the clinical applications, as well as the possible threats associated with the use of miRNAs to combat the deleterious consequences of SARS-CoV-2 infection. METHODOLOGY: This article was compiled to evaluate how the miRNAs are involved in the SARS-CoV-2 pathogenesis and infection, and their potential functions which could help in the development of therapeutic targets against the COVID-19. The sources of the collected information include the several journals, databases and scientific search engines such as the Google scholar, Pubmed, Science direct, official website of WHO, among the other sites. The investigations on the online platform were conducted using the keywords miRNA biogenesis, miRNA and ACE2 interaction, therapeutic role of miRNAs against SARS-CoV-2 and miRNA therapy side effects.

resultsThis review has highlighted that the miRNAs can be exploited to generate potential therapeutic targets against the COVID-19. Changes in the miRNA levels following viral replication are an essential component of the host response to infection. The collection and modification of miRNA modulates may help to minimize the deleterious consequences of SARS-CoV-2 infection, such as by controlling or inhibiting the generation of cytokines and chemokines. The degradation of viral RNA by the cellular miRNAs, along with the reduced expression of ACE2 receptors, can substantially reduce the viral load. Specific miRNAs have been found to have an antiviral influence, allowing the immune system to combat the infection or forcing the virus into a latency stage.

conclusionThis review summarizes several studies revealing the involvement of miRNAs in diverse and complex processes during the infection process of SARS-CoV-2. The miRNAs can substantially reduce the viral load by degradation of viral RNA and reduced expression of ACE2 receptors, besides mitigating the deleterious consequences of the exaggerated secretion of cytokines. Extensive investigations need to be done by the scientific community to utilize the miRNA based strategies for the development of effective therapeutic targets against the COVID-19.

Indexed as

COVID-19 Drug TreatmentMicroRNAsAngiotensin-Converting Enzyme 2CytokinesHumansRNA, ViralSARS-CoV-2Angiotensin-Converting Enzyme 2CytokinesMicroRNAsRNA, ViralACE2 receptorCOVID-19MiRNASARS-CoV-2Therapeutics

Identifiers

PMID35751930
PMCPMC9221922
OpenAlexW4283257461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.